Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
903.5 USD | +1.44% | -0.34% | +2.87% |
26/04 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
26/04 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.87% | 96.09B | |
-1.17% | 102B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B | |
+310.48% | 8.78B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals : , Sanofi's Supplemental Biologics License Application for Asthma Treatment Candidate Accepted for Review by FDA